Rising to the challenge of the renal anatomy1,2

  • JELMYTO combines mitomycin with sterile hydrogel, designed with a proprietary reverse-thermal technology (RTGelTM) that allows it to transform from a chilled liquid at instillation into a gel at body temperature
  • Once instilled under fluoroscopy into the renal pelvis via catheter (or nephrostomy tube), JELMYTO fills and conforms to the complex anatomy—thereby exposing tumors to JELMYTO

The technology of JELMYTO makes a complete response possible1,2:

Instilled via catheter or nephrostomy tube into the renal pelvis

Fills and conforms to the renal collecting system

Delivers sustained exposure of mitomycin for up to 4 to 6 hours

of patients treated with JELMYTO achieved a complete response

JELMYTO is the first and only FDA-approved treatment for low-grade UTUC1

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please click here for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.

Please click here for Full Prescribing Information, Instructions for Pharmacy and Instructions for Administration.